Singapore markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.34-0.01 (-0.12%)
At close: 04:00PM EST
8.08 -0.26 (-3.12%)
After hours: 06:47PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 709.33M
Enterprise value 903.25M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)2.95
Price/book (mrq)N/A
Enterprise value/revenue 3.78
Enterprise value/EBITDA -3.67

Trading information

Stock price history

Beta (5Y monthly) 0.87
52-week change 3-32.52%
S&P500 52-week change 3-9.85%
52-week high 314.11
52-week low 35.58
50-day moving average 37.81
200-day moving average 38.76

Share statistics

Avg vol (3-month) 31.28M
Avg vol (10-day) 3981.24k
Shares outstanding 577.78M
Implied shares outstanding 6N/A
Float 870.84M
% held by insiders 11.92%
% held by institutions 1105.12%
Shares short (12 Jan 2023) 410.17M
Short ratio (12 Jan 2023) 45.63
Short % of float (12 Jan 2023) 416.54%
Short % of shares outstanding (12 Jan 2023) 413.07%
Shares short (prior month 14 Dec 2022) 49.68M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022

Profitability

Profit margin -116.54%
Operating margin (ttm)-93.76%

Management effectiveness

Return on assets (ttm)-21.67%
Return on equity (ttm)-1,657.06%

Income statement

Revenue (ttm)239.06M
Revenue per share (ttm)3.09
Quarterly revenue growth (yoy)-44.90%
Gross profit (ttm)250.27M
EBITDA -220.65M
Net income avi to common (ttm)-278.61M
Diluted EPS (ttm)-2.75
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)286.8M
Total cash per share (mrq)3.69
Total debt (mrq)480.72M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.62
Book value per share (mrq)-1.25

Cash flow statement

Operating cash flow (ttm)-193.49M
Levered free cash flow (ttm)-116.74M